Recently, two antagonists of HIF-2α (PT2385 and PT2399) have shown promising results in inhibiting tumor growth and angiogenesis in ccRCC [40,81,82,83] highlighting HIF-2α as potential therapeutic target. This evidence concerns the gene EPAS1 and neoplasm.